Mohamed Farghaly
Dubai Medical college, Dubai
Title: Treatment pattern for Newley diagnosed Type 2 diabetes in Dubai
Biography
Biography: Mohamed Farghaly
Abstract
Objective: The objective of the study is to understand the treatment patterns among newly diagnosed T2DM patients in Dubai and make broad-level comparisons against the ADA’s recommendations.
Method: A retrospective database analysis was conducted using Dubai claims database. All patients with a T2DM diagnosis were identified during July 2014 to March 2016 and their first diagnosis was assigned as the index diagnosis. Patients with a diabetes diagnosis or use of Anti-Diabetic Therapy (ADT) during prior six months were excluded. Patients were continuously enrolled during 6 months before and 12 months after the index diagnosis.
Result: The final study cohort included 25,320 patients, of which 63.1% did not receive any ADT during 12 months follow-up from the index diagnosis. For the remaining 9,349 patients, 54.6% patients received the first ADT on index diagnosis date, while the mean time to ADT for the remaining 45.4% patients was 68.6 days. The most common first ADT was metformin received by 88.9% patients, of which 42.9% received it as a monotherapy while remaining 57.1% received it in combination with another drug. The proportion of patients having their first ADT as combination therapy or insulin was 50.3% and 4.3%, respectively. Mean number of oral prescriptions during follow-up was 2.9. The average most recent HbA1c value before initiating monotherapy, combination therapy and insulin-based therapy was 7.0, 8.4 and 9.1, respectively.